Cai Maoping, Ge Shengdong, Hong Yaying, Chen Yao, Ren Yang-Zi, Zhong Dacai, Chen Mingkun, Liu Yuan, Chen Zhe-Sheng, Feng Ninghan, Chen Zhanghui, Zhao Shan-Chao
Department of Urology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, 510920, Guangdong, People's Republic of China.
The Third Clinical College, Southern Medical University, Guangzhou, 510630, Guangdong, People's Republic of China.
Mol Med. 2025 Jan 29;31(1):30. doi: 10.1186/s10020-025-01080-1.
Prostate cancer (PCa) is a highly common type of malignancy and affects millions of men in the world since it is easy to recur or emerge therapy resistance. Therefore, it is urgent to find novel treatments for PCa patients. In the current study, we found that tegaserod maleate (TM), an FDA-approved agent, inhibited proliferation, colony formation, migration as well as invasion, caused the arrest of the cell cycle, and promoted apoptosis of PCa cells in vitro. In addition, TM suppressed the tumor growth in the cell-derived xenograft (CDX) mouse model in vivo. Mechanistically, TM exerted anti-tumor effects via downregulating GLI2, and its downtream targets, thus inhibiting the sonic hedgehog (SHH) signaling pathway. In brief, our findings demonstrated that TM effectively inhibited the activities of PCa cells by suppressing the SHH signaling pathway and provided a potential new agent for the treatment of PCa.
前列腺癌（PCa）是一种非常常见的恶性肿瘤，由于其易于复发或产生治疗抵抗性，影响着全球数百万男性。因此，迫切需要为前列腺癌患者找到新的治疗方法。在当前的研究中，我们发现替加色罗马来酸盐（TM），一种已获美国食品药品监督管理局（FDA）批准的药物，在体外可抑制前列腺癌细胞的增殖、集落形成、迁移以及侵袭，导致细胞周期停滞，并促进细胞凋亡。此外，TM在体内细胞源异种移植（CDX）小鼠模型中抑制肿瘤生长。从机制上讲，TM通过下调GLI2及其下游靶点发挥抗肿瘤作用，从而抑制音猬因子（SHH）信号通路。简而言之，我们的研究结果表明，TM通过抑制SHH信号通路有效抑制前列腺癌细胞的活性，并为前列腺癌的治疗提供了一种潜在的新药物。
